LOGIN  |  REGISTER
Cue Biopharma
Compass Therapeutics

Zynex to Present at the RBC Capital Markets Global Healthcare Conference

May 09, 2024 | Last Trade: US$8.25 0.15 -1.79

ENGLEWOOD, Colo., May 9, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held May 14-15, 2024.

Zynex's presentation will be held in person and webcast live on May 15 at 3:05 PM ET at the InterContinental Barclay Hotel in New York, NY. You can listen to the webcast at Zynex Investor Presentation Webcast. Dan Moorhead, CFO, will be available for one-on-one meetings on May 15.

To receive additional information, register to attend, or schedule a one-on-one meeting, email Mary Fleming at This email address is being protected from spambots. You need JavaScript enabled to view it. or Jennifer Nguyen at This email address is being protected from spambots. You need JavaScript enabled to view it.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB